Nyxoah's Genio reduces median apnea-hypopnea index 74.3% in 12-month study of CCC patients

• Nyxoah presented full 12-month ACCCESS pivotal study results for Genio at the ISSS meeting on October 15, 2026.
• Genio met both primary efficacy endpoints in obstructive sleep apnea patients with complete concentric collapse, reducing breathing disruptions during sleep.
• No device- or procedure-related serious adverse events occurred through 12 months; patients reported reduced daytime sleepiness and improved quality of life.
• A supplemental FDA application seeks to expand Genio’s indication to these patients, who lack a commercially available US neurostimulation option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nyxoah SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610151605PRIMZONEFULLFEED1001278204) on October 15, 2026, and is solely responsible for the information contained therein.